Syntimmune is a biotechnology company that develops antibody therapeutics for the treatment of autoimmune diseases.
Business Model:
Revenue: $9M
Employees: 11-50
Syntimmune was acquired by
Alexion Pharmaceuticals.
The acquisition happend on 2018-09-26.
Details of the transaction were not public
Address: 116 Huntington Avenue
City: Boston
State: MA
Zip: 02116
Country: US
Syntimmune is a biotechnology company that develops antibody therapeutics for the treatment of autoimmune diseases.
Contact Phone:
+16172064220
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 3/2016 | Series A | 3 | $10M |
Baxalta Ventures Partners Innovation Fund Apple Tree Partners Apple Tree Partners Baxalta Ventures Baxalta Ventures Partners Innovation Fund Apple Tree Partners Apple Tree Partners Baxalta Ventures |
11/2016 | Series A | 3 | $8M |
Partners Innovation Fund Baxalta Ventures Apple Tree Partners Partners Innovation Fund Baxalta Ventures Apple Tree Partners |
6/2017 | Series B | 3 | $50M |
Apple Tree Partners Partners Innovation Fund Baxalta Ventures Apple Tree Partners Apple Tree Partners Partners Innovation Fund Baxalta Ventures Apple Tree Partners |
10/2014 | Series A | 3 | $8M |
Baxalta Ventures Partners Innovation Fund Apple Tree Partners Baxalta Ventures |
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|